Phenylpiracetam: A Literature Course

This page is a structured reading guide to the published literature on phenylpiracetam. It summarises what individual papers reported, in the models they used, and it marks where the published record is silent. This page is for educational purposes only and is not medical advice; consult a licensed physician before making any health decision. No dose, schedule, or protocol is described here, because the verified literature summarised below does not supply human dosing evidence that could be reported responsibly.

The course runs in six modules. Each module closes with a short limits of the evidence note, and the page ends with an explicit list of questions the studies did not test.

Module 1 — What Phenylpiracetam Is and How It Has Been Studied

Definition and chemical class

Phenylpiracetam is a small synthetic molecule built on the 2-oxopyrrolidine (pyrrolidinone) ring that defines the so-called racetam family, with a phenyl group added to the side chain. Its family relationships were mapped in a 2010 review in Drugs, which surveyed piracetam and piracetam-like drugs from basic science through to proposed clinical applications in central nervous system disorders (PMID 20166767). That review is the standard entry point for understanding why compounds in this class are grouped together chemically even when their reported pharmacology differs.

Names and forms

The compound appears in the literature under more than one name. A 2024 review in the Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova discussed the pharmacological effects of fonturacetam, marketed as Actitropil, and prospects for its clinical use, using that nomenclature throughout (PMID 39269293). Readers searching the database should expect both "phenylpiracetam" and "fonturacetam" to return relevant records.

Because the molecule carries a stereocentre, it exists as two enantiomers, and the experimental literature treats them separately. One 2017 study in Pharmacology, Biochemistry, and Behavior investigated S-phenylpiracetam specifically (PMID 28743458), while a 2020 paper in Inflammopharmacology investigated R-phenylpiracetam in mouse inflammation models (PMID 32279140). Findings attached to one enantiomer cannot be assumed to describe the racemic mixture.

Synthetic and analytical context

Part of the surrounding literature is methodological rather than pharmacological. A 2022 paper in Molecules described asymmetric Michael addition routes used in the synthesis of β-substituted GABA derivatives, the broader structural territory that phenyl-substituted analogues occupy (PMID 35744921), and a 2016 paper in Chemistry reported modified reactivity of donor–acceptor cyclopropanes towards nucleophiles in reactions with nitroalkanes, a methodology relevant to building such scaffolds (PMID 26880270). On the detection side, a 2021 forensic toxicology paper described a molecularly imprinted sorbent for biological-fluid sample preparation (PMID 34814644), reflecting the fact that much of the recent interest in this compound class is analytical.

Limits of the evidence — Module 1

• The verified record contains reviews, rodent pharmacology, chemistry methodology and surveillance reports; it does not contain large randomised human trials of phenylpiracetam.
• Enantiomer-specific findings are not interchangeable with racemic material.
• Several relevant primary papers are published in Russian-language journals, so English abstracts may be the only accessible description of methods.

Module 2 — Mechanism as Described in the Literature

Dopamine transporter inhibition

The mechanistic label used most consistently in recent primary work is dopamine transporter (DAT) inhibition. The 2017 Pharmacology, Biochemistry, and Behavior study characterised S-phenylpiracetam as a selective DAT inhibitor while examining body-weight and locomotor endpoints (PMID 28743458). The 2020 Inflammopharmacology study likewise described R-phenylpiracetam as a DAT inhibitor when reporting neuroprotective and anti-inflammatory activity in experimental models of inflammation in male mice (PMID 32279140). Notably, these two papers attach the same transporter-level description to different enantiomers and different endpoints.

Class-level mechanisms inherited from racetam research

Older mechanistic discussion is framed at the level of the chemical family. The 2010 Drugs review summarised the basic science proposed for piracetam and piracetam-like drugs, including membrane and neurotransmission-related hypotheses, alongside the CNS disorders in which such agents had been investigated (PMID 20166767). Because that review covers a family rather than one molecule, its mechanistic statements should not be read as measurements made with phenylpiracetam.

Mitochondrial and haemostatic lines of work

Two Russian-language experimental papers address adjacent mechanisms in metabolically compromised rodents. A 2015 paper examined the role of the functional state of neuronal mitochondria in the cerebral cortex in the mechanisms of nootropic activity of neuroprotectors in rats with alloxan hyperglycemia (PMID 25898541). A 2014 paper in the Bulletin of Experimental Biology and Medicine studied mechanisms for the antiaggregant activity of pyrrolidone derivatives in rats with chronic hyperglycemia (PMID 24824701). Both concern the pyrrolidone/neuroprotector category rather than naming phenylpiracetam in their titles, so they belong in a mechanism module only as class context.

Limits of the evidence — Module 2

• "DAT inhibitor" is a descriptor applied in the cited papers; the verified set does not provide comparative binding affinities that could be summarised here.
• Mechanistic claims drawn from class reviews or from pyrrolidone-derivative studies are inferential when applied to phenylpiracetam itself.
• No verified human mechanistic study — imaging, receptor occupancy or biomarker work — appears in this set.

Module 3 — Reported Outcomes by Study

The table below lists what each cited paper examined and what researchers reported, without extrapolation. No efficacy conclusion for people is implied by any row.

Limits of the evidence — Module 3

• Every outcome above except the review material comes from animal or in-vitro work; species, route and model differences limit translation.
• The verified set contains no human cognitive-performance trial of phenylpiracetam, so no statement about memory, attention or fatigue in people can be made here.
• Single studies in single laboratories, without independent replication described in this set, are hypothesis-generating rather than conclusive.

Module 4 — Phenylpiracetam Side Effects: What Studies Report

The most striking feature of the published safety record is how thin it is. In the verified literature, adverse events are discussed mainly in the context of products that contain the compound without authorisation, not in controlled safety trials.

A 2025 market surveillance study published in the Journal of Xenobiotics, carried out by 12 official medicines control laboratories, reported on the occurrence of illicit "smart drugs" or nootropics in Europe and Australia and on the dangers associated with them (PMID 40558871). A 2023 review in Drug Testing and Analysis examined unauthorized ingredients in "nootropic" dietary supplements, covering their history, pharmacology, prevalence, international regulations and potential as doping agents (PMID 37357012). A 2021 analysis in Neurology: Clinical Practice reported that five unapproved drugs were found in supplements sold for cognitive enhancement (PMID 34484905). Collectively, these papers frame the risk discussion around exposure to pharmacologically active substances outside medical supervision and outside any approved labelling.

On the experimental side, the 2017 rodent study reported that S-phenylpiracetam reduced body-weight gain without influencing locomotor activity, an observation about a physiological endpoint rather than a toxicology finding (PMID 28743458). The 2024 review of fonturacetam discussed its pharmacological effects and clinical prospects (PMID 39269293), and readers evaluating tolerability should consult that primary source directly, since the accessible abstract does not enumerate an adverse-event table.

Limits of the evidence — Module 4

• No verified paper in this set reports a quantified adverse-event frequency, a dose–toxicity relationship, or a long-term safety follow-up for phenylpiracetam.
• Absence of published adverse events is not evidence of safety; it reflects the absence of systematic safety studies in the accessible record.
• Surveillance and supplement-analysis papers describe product-quality and exposure risks, which are distinct from a pharmacological side-effect profile.

Module 5 — Pharmacokinetics Where Data Exist

The verified literature does not supply human absorption, distribution, metabolism or elimination parameters for phenylpiracetam that could be reported here. What it does supply is analytical infrastructure. A 2021 forensic toxicology paper described a molecularly imprinted sorbent developed for sample preparation from biological fluids, the kind of method that underpins measurement of such compounds in blood or urine (PMID 34814644). The 2023 review of unauthorized nootropic ingredients addressed detection and the potential of these substances as doping agents, which presupposes that they are measurable in biological matrices (PMID 37357012).

Class-level pharmacology, including how piracetam-like molecules have been characterised in preclinical and clinical settings, was summarised in the 2010 Drugs review (PMID 20166767), and the 2024 fonturacetam review discussed pharmacological effects relevant to proposed clinical use (PMID 39269293). Neither abstract in this set provides half-life, bioavailability or clearance figures, and inventing such numbers would be the opposite of an evidence summary.

Limits of the evidence — Module 5

• No half-life, C_max, T_max, protein-binding or metabolite data for phenylpiracetam appear in the verified set.
• Nothing in this set addresses drug–drug interactions, renal or hepatic impairment, age effects, or enantiomer-specific kinetics.
• Analytical-method papers demonstrate detectability, not pharmacokinetic behaviour.

Module 6 — Regulatory Status, Stated Factually

Regulatory status differs sharply by jurisdiction, and the literature reflects that split. A 2024 Russian-language review described fonturacetam under the trade name Actitropil and discussed prospects for its clinical use (PMID 39269293), indicating a marketed medicinal product in that setting. In the United States, phenylpiracetam is not an FDA-approved drug product and is not a lawful dietary-supplement ingredient; a 2021 analysis reported that unapproved drugs were nonetheless found in supplements marketed for cognitive enhancement (PMID 34484905), and a 2023 review documented the prevalence of unauthorized nootropic ingredients alongside the relevant international regulations and their standing as potential doping agents (PMID 37357012). A 2025 surveillance study by 12 official medicines control laboratories reported on illicit smart drugs circulating in Europe and Australia (PMID 40558871).

Material offered to laboratories is commonly designated research-use-only, meaning it is not manufactured, tested or labelled for human administration. In the United States, pharmacy compounding under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act generally requires that a bulk drug substance be a component of an FDA-approved product, appear in an applicable USP or NF monograph, or be included on an FDA bulk-substances list; substances meeting none of those criteria are not eligible for compounding on that basis. Athletes are additionally governed by anti-doping rules, and the doping relevance of nootropic ingredients was one focus of the 2023 review (PMID 37357012). This section describes published regulatory facts and is not legal advice; rules differ by country and state and change over time.

Limits of the evidence — Module 6

• Regulatory classifications change; the cited papers capture the position at the time of publication.
• Approval in one jurisdiction says nothing about legality, labelling or product quality elsewhere.
• The surveillance literature reports what laboratories found in sampled products, which cannot be generalised to every product on every market.

What the Studies Did Not Test

Reading the verified record as a whole, the following questions remain unanswered within it:

1. Human efficacy. No trial in this set measured cognition, mood, fatigue or athletic performance in people taking phenylpiracetam.
2. Dose–response in humans. No human dose-ranging study is present, which is why no dose appears anywhere on this page.
3. Long-term exposure. No study in this set followed animals or people for extended periods to assess tolerance, dependence, withdrawal or cumulative organ effects.
4. Comparative effectiveness. No head-to-head comparison against approved medicines or against other racetams was reported in this set.
5. Special populations. Pregnancy, lactation, paediatric use, older adults, and people with cardiovascular, psychiatric, renal or hepatic disease were not addressed in the verified papers.
6. Enantiomer equivalence. Because the 2017 study examined S-phenylpiracetam (PMID 28743458) and the 2020 study examined R-phenylpiracetam (PMID 32279140), whether racemic material behaves like either single enantiomer was not established here.

The honest summary is that phenylpiracetam has an active preclinical and analytical literature, a marketed product in at least one jurisdiction as described in a 2024 review (PMID 39269293), and a documented presence in unauthorised consumer products as reported by surveillance and supplement-analysis papers (PMID 40558871). Those are three different bodies of evidence, and conflating them is the most common error in popular writing about this compound.

References

• Piracetam and piracetam-like drugs: from basic science to novel clinical applications to CNS disorders (Drugs, 2010)
• A study of the mechanisms for antiaggregant activity of pyrrolidone derivatives in rats with chronic hyperglycemia (Bulletin of Experimental Biology and Medicine, 2014)
• Role of functional state of neuronal mitochondria of cerebral cortex in mechanisms of nootropic activity of neuroprotectors in rats with alloxan hyperglycemia (Eksperimental'naia i Klinicheskaia Farmakologiia, 2015)
• From Umpolung to Alternation: Modified Reactivity of Donor-Acceptor Cyclopropanes Towards Nucleophiles in Reaction with Nitroalkanes (Chemistry, 2016)
• S-phenylpiracetam, a selective DAT inhibitor, reduces body weight gain without influencing locomotor activity (Pharmacology, Biochemistry, and Behavior, 2017)
• Neuroprotective and anti-inflammatory activity of DAT inhibitor R-phenylpiracetam in experimental models of inflammation in male mice (Inflammopharmacology, 2020)
• Five Unapproved Drugs Found in Cognitive Enhancement Supplements (Neurology: Clinical Practice, 2021)
• Molecularly imprinted sorbent for biological fluids sample preparation in forensic toxicology (Sudebno-Meditsinskaia Ekspertiza, 2021)
• Asymmetric Michael Addition in Synthesis of β-Substituted GABA Derivatives (Molecules, 2022)
• Unauthorized ingredients in "nootropic" dietary supplements: A review of the history, pharmacology, prevalence, international regulations, and potential as doping agents (Drug Testing and Analysis, 2023)
• Pharmacological effects of fonturacetam (Actitropil) and prospects for its clinical use (Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova, 2024)
• The Occurrence of Illicit Smart Drugs or Nootropics in Europe and Australia and Their Associated Dangers: Results from a Market Surveillance Study by 12 Official Medicines Control Laboratories (Journal of Xenobiotics, 2025)